For the quarter ending 2026-03-31, APLS made $268,295K in revenue. $18,348K in net income. Net profit margin of 6.84%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 268,295 | 199,913 | 458,578 | 178,494 |
| Cost of sales | 40,547 | 29,719 | 24,531 | 13,626 |
| Research and development | 76,958 | 74,233 | 68,186 | 67,015 |
| Selling, general and administrative | 124,323 | 147,103 | 142,678 | 131,139 |
| Total operating expenses | 241,828 | 251,055 | 235,395 | 211,780 |
| Net operating income/(gain) | 26,467 | -51,142 | 223,183 | -33,286 |
| Interest income | 2,914 | 3,502 | 4,376 | 2,607 |
| Interest expense | 10,317 | 10,847 | 11,279 | 11,152 |
| Other income/(expense), net | 88 | -151 | 37 | 146 |
| Net income/(gain) before taxes | 19,152 | -58,638 | 216,317 | -41,685 |
| Income tax expense | 496 | 313 | 602 | 466 |
| Net income/(gain) | 18,656 | -58,951 | 215,715 | -42,151 |
| Unrealized loss/(gain) on pension plans | - | 30 | -137 | - |
| Foreign currency translation | -308 | 327 | 32 | 485 |
| Total other comprehensive income/(loss) | -308 | 297 | 169 | 485 |
| Comprehensive income/(gain), net of tax | 18,348 | -58,654 | 215,884 | -41,666 |
| Basic EPS | 0.15 | -0.463 | 1.71 | -0.33 |
| Diluted EPS | 0.15 | -0.425 | 1.67 | -0.33 |
| Basic Average Shares | 127,682,000 | 126,679,000 | 126,424,000 | 126,024,000 |
| Diluted Average Shares | 131,424,000 | 137,876,000 | 130,067,000 | 126,024,000 |
Apellis Pharmaceuticals, Inc. (APLS)
Apellis Pharmaceuticals, Inc. (APLS)